{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:42:22Z","timestamp":1776116542068,"version":"3.50.1"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1248\/bpb.b22-00284","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T22:12:46Z","timestamp":1659305566000},"page":"1180-1184","source":"Crossref","is-referenced-by-count":9,"title":["Ibudilast Reduces IL-6 Levels and Ameliorates Symptoms in Lipopolysaccharide-Induced Sepsis Mice"],"prefix":"10.1248","volume":"45","author":[{"given":"Naoko","family":"Kadota","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akari","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sawamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunari","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The third international consensus definitions for sepsis and septic shock (Sepsis-3). <i>JAMA<\/i>, <b>315<\/b>, 801\u2013810 (2016).","DOI":"10.1001\/jama.2016.0287"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. <i>Crit. Care Med.<\/i>, <b>41<\/b>, 1167\u20131174 (2013).","DOI":"10.1097\/CCM.0b013e31827c09f8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cohen J, Opal S, Calandra T. Sepsis studies need new direction. <i>Lancet Infect. Dis.<\/i>, <b>12<\/b>, 503\u2013505 (2012).","DOI":"10.1016\/S1473-3099(12)70136-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Savva A, Roger T. Targeting Toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. <i>Front. Immunol.<\/i>, <b>4<\/b>, 387 (2013).","DOI":"10.3389\/fimmu.2013.00387"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Fink MP, Warren HS. Strategies to improve drug development for sepsis. <i>Nat. Rev. Drug Discov.<\/i>, <b>13<\/b>, 741\u2013758 (2014).","DOI":"10.1038\/nrd4368"},{"key":"6","unstructured":"6) Fox RJ, Coffey CS, Conwit R, <i>et al.<\/i> Phase 2 trial of ibudilast in progressive multiple sclerosis. <i>N. Engl. J. Med.<\/i>, <b>379<\/b>, 846\u2013855 (2018)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fujita M, Tamano R, Yoneda S, Omachi S, Yogo E, Rokushima M, Shinohara S, Sakaguchi G, Hasegawa M, Asaki T. Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: different inhibitory mechanism on spinal microglia from minocycline and propentofylline. <i>Eur. J. Pharmacol.<\/i>, <b>833<\/b>, 263\u2013274 (2018).","DOI":"10.1016\/j.ejphar.2018.06.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ishikawa S, Sawamoto A, Okuyama S, Nakajima M. T-cell activation-inhibitory assay to screen caloric restriction mimetics drugs for drug repositioning. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 550\u2013556 (2021).","DOI":"10.1248\/bpb.b20-00889"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. <i>J. Exp. Med.<\/i>, <b>169<\/b>, 333\u2013338 (1989).","DOI":"10.1084\/jem.169.1.333"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H, Matsuura Y, Kishimoto T. IL-6 <i>trans<\/i>-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>117<\/b>, 22351\u201322356 (2020).","DOI":"10.1073\/pnas.2010229117"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Honda S, Sato K, Totsuka N, Fujiyama S, Fujimoto M, Miyake K, Nakahashi-Oda C, Tahara-Hanaoka S, Shibuya K, Shibuya A. Marginal zone B cells exacerbate endotoxic shock <i>via<\/i> interleukin-6 secretion induced by Fc\u03b1\/\u03bcR-coupled TLR4 signalling. <i>Nat. Commun.<\/i>, <b>7<\/b>, 11498 (2016).","DOI":"10.1038\/ncomms11498"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lee JW, Bae CJ, Choi YJ, Kim SI, Kwon YS, Lee HJ, Kim SS, Chun W. 3,4,5-trihydroxycinnamic acid inhibits lipopolysaccharide (LPS)-induced inflammation by Nrf2 activation <i>in vitro<\/i> and improves survival of mice in LPS-induced endotoxemia model <i>in vivo.<\/i> <i>Mol. Cell. Biochem.<\/i>, <b>390<\/b>, 143\u2013153 (2014).","DOI":"10.1007\/s11010-014-1965-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kim SH, Lee TH, Lee SM, Park JH, Park KH, Jung M, Jung H, Mohamed MAA, Baek N-I, Chung IS, Kim J. Cynandione A attenuates lipopolysaccharide-induced production of inflammatory mediators <i>via<\/i> MAPK inhibition and NF-\u03baB inactivation in RAW264.7 macrophages and protects mice against endotoxin shock. <i>Exp. Biol. Med. <\/i>(Maywood), <b>240<\/b>, 946\u2013954 (2015).","DOI":"10.1177\/1535370214558022"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hwang JS, Kim KH, Park J, Kim SM, Cho H, Lee Y, Han IO. Glucosamine improves survival in a mouse model of sepsis and attenuates sepsis-induced lung injury and inflammation. <i>J. Biol. Chem.<\/i>, <b>294<\/b>, 608\u2013622 (2019).","DOI":"10.1074\/jbc.RA118.004638"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Chang KC, Ko YS, Kim HJ, Nam DY, Lee DU. 13-Methylberberine reduces HMGB1 release in LPS-activated RAW264.7 cells and increases the survival of septic mice through AMPK\/P38 MAPK activation. <i>Int. Immunopharmacol.<\/i>, <b>40<\/b>, 269\u2013276 (2016).","DOI":"10.1016\/j.intimp.2016.08.022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Williams L, Bradley L, Smith A, Foxwell B. Signal Transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. <i>J. Immunol.<\/i>, <b>172<\/b>, 567\u2013576 (2004).","DOI":"10.4049\/jimmunol.172.1.567"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10\/STAT3-mediated anti-inflammatory response: recent developments and future challenges. <i>Brief. Funct. Genomics<\/i>, <b>12<\/b>, 489\u2013498 (2013).","DOI":"10.1093\/bfgp\/elt028"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Higa M, Oka M, Fujihara Y, Masuda K, Yoneda Y, Kishimoto T. Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>115<\/b>, E1214\u2013E1220 (2018).","DOI":"10.1073\/pnas.1719921115"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette\u2013Guerin and lipopolysaccharide. <i>Hepatology<\/i>, <b>29<\/b>, 1752\u20131759 (1999).","DOI":"10.1002\/hep.510290610"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EK. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. <i>Thromb. Haemost.<\/i>, <b>61<\/b>, 459\u2013462 (1989).","DOI":"10.1055\/s-0038-1646614"},{"key":"21","unstructured":"21) Kidokoro A, Iba T, Hong J. Role of DIC in multiple organ failure. <i>Int. J. Surg. Investig.<\/i>, <b>2<\/b>, 73\u201380 (2000)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Schwenkgrub J, Zaremba M, Mirowska-Guzel D, Kurkowska-Jastrz\u0119bska I. Ibudilast: a non-selective phosphodiesterase inhibitor in brain disorders. <i>Postepy Hig. Med. Dosw.<\/i>, <b>71<\/b>, 137\u2013148 (2017).","DOI":"10.5604\/01.3001.0010.3798"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) \u015awierczek A, Pociecha K, \u015alusarczyk M, Ch\u0142o\u0144-Rzepa G, Ba\u015b S, Mlynarski J, Wi\u0119ckowski K, Zadro\u017cna M, Nowak B, Wyska E. Comparative assessment of the new PDE7 inhibitor\u2014GRMS-55 and lisofylline in animal models of immune-related disorders: a PK\/PD modeling approach. <i>Pharm. Res.<\/i>, <b>37<\/b>, 19 (2020).","DOI":"10.1007\/s11095-020-2764-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Speer EM, Diago-Navarro E, Ozog LS, Raheel M, Levy O, Fries BC. A neonatal murine <i>Escherichia coli<\/i> sepsis model demonstrates that adjunctive pentoxifylline enhances the ratio of anti- <i>vs.<\/i> pro-inflammatory cytokines in blood and organ tissues. <i>Front. Immunol.<\/i>, <b>11<\/b>, 577878 (2020).","DOI":"10.3389\/fimmu.2020.577878"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, Tracey KJ. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. <i>J. Biol. Chem.<\/i>, <b>280<\/b>, 36541\u201336544 (2005).","DOI":"10.1074\/jbc.C500243200"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K, Lolis EJ. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>107<\/b>, 11313\u201311318 (2010).","DOI":"10.1073\/pnas.1002716107"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Nishiyama K, Numaga-Tomita T, Fujimoto Y, Tanaka T, Toyama C, Nishimura A, Yamashita T, Matsunaga N, Koyanagi S, Azuma YT, Ibuki Y, Uchida K, Ohdo S, Nishida M. Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. <i>Br. J. Pharmacol.<\/i>, <b>176<\/b>, 3723\u20133738 (2019).","DOI":"10.1111\/bph.14777"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ruiz-P\u00e9rez D, Benito J, Polo G, Largo C, Aguado D, Sanz L, G\u00f3mez de Segura IA. The effects of the toll-like receptor 4 antagonist, ibudilast, on sevoflurane\u2019s minimum alveolar concentration and the delayed remifentanil-induced increase in the minimum alveolar concentration in rats. <i>Anesth. Analg.<\/i>, <b>122<\/b>, 1370\u20131376 (2016).","DOI":"10.1213\/ANE.0000000000001171"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ishibashi J, Saito K, Ishizaki T, Horie I, Isohama Y. Ibudilast suppresses MUC5AC mucus production through inhibition of ERK1\/2 phosphorylation. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 404\u2013409 (2021).","DOI":"10.1248\/bpb.b20-00798"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Li X, Zou Y, Fu Y-Y, Xing J, Wang K-Y, Wan P-Z, Wang M, Zhai X-Y. Ibudilast attenuates folic acid-induced acute kidney injury by blocking pyroptosis through TLR4-mediated NF-\u03baB and MAPK signaling pathways. <i>Front. Pharmacol.<\/i>, <b>12<\/b>, 650283 (2021).","DOI":"10.3389\/fphar.2021.650283"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/8\/45_b22-00284\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T03:30:34Z","timestamp":1659756634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/8\/45_b22-00284\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00284","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"b22-00284"}}